Vertex Pharmaceuticals Incorporated VRTX

Full chart Compare
Set alert

Price alert · VRTX

All alert types
530.76 USD -22.39 (-4.05%)

At closeNov 3, 2026, 7:36 PM EST

528.28 -2.48 -0.47%

After hours · Nov 3, 7:36 PM ET

529.15 Day range 561.96
403.16 52-week range 568.67
YTD
+17.07%
1 year
+24.59%
Market cap
134.53B
Revenue (ttm)
12.59B
Profit margin
35.00%
EPS (ttm)
15.54
Shares out
253.46M
P/E ratio
34.15
Forward P/E
25.99
YTD return
+17.07%
1-year return
+24.59%
Volume
2.37M
Avg volume
1.22M
Open
558.44
Previous close
553.15
Day's range
529.15 – 561.96
52-week range
403.16 – 568.67
Beta
0.28
Analysts
Buy
Price target
576.29 (+8.6%)
Earnings date
Feb 11, 2027

5D +14.84 (+2.87%)

520540560WedThuFriMonTue531.20

Key statistics

Enterprise value
134.33B
PEG ratio
2.16
Price / sales
10.69
Price / book
6.64
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
12.50%
Free cash flow
2.63B
Total cash
7.85B
Total debt
1.98B
Return on equity
23.54%
Short % of float
1.90%
50-day average
523.32
200-day average
479.79

Financials — quick view

All financials
VRTX Revenue — quarterly 3.33B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
VRTX Net income — quarterly 1.10B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
VRTX EPS — quarterly 4.34
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

VRTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20264.64———
Nov 2, 2026Sep 30, 20264.824.76-0.06-1.24%
Aug 3, 2026Jun 30, 20264.744.73-0.01-0.21%
May 4, 2026Mar 31, 20264.244.47+0.23+5.42%
Feb 12, 2026Dec 31, 20255.115.03-0.08-1.57%
Nov 3, 2025Sep 30, 20254.574.80+0.23+5.03%

Upgrades / downgrades

VRTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 3, 2026JP MorganmainOverweightOverweight
Nov 3, 2026Goldman SachsmainBuyBuy
Nov 3, 2026Morgan StanleymainOverweightOverweight
Nov 3, 2026ScotiabankmainSector OutperformSector Outperform
Nov 3, 2026UBSmainBuyBuy
Nov 3, 2026TD CowenmainBuyBuy

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
vrtx.com

News

Your note

Sign in to keep a note on VRTX — it syncs with the Stock Master app.

Insider holders

VRTX insider holders
InsiderRelationLatest transactionDateShares held
ALTSHULER DAVIDOfficerStock Award(Grant)Jan 21, 202634,477
ARBUCKLE STUART AChief Operating OfficerStock Award(Grant)May 12, 2025100,751
ATKINSON EDWARD MORROW IIIChief Technology OfficerSaleFeb 24, 202618,432
KEWALRAMANI RESHMAChief Executive OfficerSaleFeb 26, 202698,278
LEIDEN JEFFREY MOfficer and DirectorStock Award(Grant)Feb 16, 202638,784
LIU JOYOfficerSaleJun 30, 202619,131

Institution ownership

VRTX institution ownership
Holder% heldSharesValueReported
Capital World Investors10.29%26,115,01413.86BJun 29, 2026
Blackrock Inc.9.50%24,109,37312.80BJun 29, 2026
Capital Research Global Investors7.68%19,490,63710.34BJun 29, 2026
Vanguard Capital Management LLC6.53%16,580,7138.80BJun 29, 2026
State Street Corporation4.68%11,871,4596.30BJun 29, 2026
Invesco Ltd.3.17%8,043,0524.27BJun 29, 2026

Fund ownership

VRTX fund ownership
Holder% heldSharesValueReported
Growth Fund of America5.09%12,908,2376.85BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,058,1284.28BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%6,576,5103.49BJun 29, 2026
AMERICAN BALANCED FUND2.14%5,428,8652.88BSep 29, 2026
Invesco QQQ Trust, Series 12.09%5,294,1262.81BSep 29, 2026
Amcap Fund1.87%4,734,9212.51BSep 29, 2026